GENETIC TECHNOLOGIES LIMITED — AGM Information 2020

Dec 9, 2020

==> picture [687 x 223] intentionally omitted <==

Authorised by George Muchnicki (CEO)

60-66 , 3065 : +61 3 8412 7000

Genetic based preventative health platform

Personalised, Precision medicine. AGM Presentation December 10th 2020

==> picture [705 x 377] intentionally omitted <==

==> picture [344 x 309] intentionally omitted <==

==> picture [212 x 251] intentionally omitted <==

Coming soon

==> picture [799 x 379] intentionally omitted <==

Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Genetic Technologies and should not be relied upon as an independent source of information. Please refer to the Company’s website and/or the Company’s filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Genetic Technologies’ control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Genetic Technologies’ current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Additionally, the INSIGHT investigator sponsored clinical trial described in this presentation is controlled by the lead investigator and therefore Genetic Technologies has no control over this clinical trial. This presentation should not be relied on as a recommendation or forecast by Genetic Technologies. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

==> picture [38 x 40] intentionally omitted <==

2

Our Board

==> picture [118 x 243] intentionally omitted <==

==> picture [584 x 195] intentionally omitted <==

==> picture [410 x 410] intentionally omitted <==

==> picture [407 x 410] intentionally omitted <==

==> picture [682 x 42] intentionally omitted <==

==> picture [278 x 33] intentionally omitted <==

==> picture [397 x 396] intentionally omitted <==

==> picture [400 x 400] intentionally omitted <==

==> picture [462 x 35] intentionally omitted <==

==> picture [650 x 75] intentionally omitted <==

==> picture [58 x 119] intentionally omitted <==

==> picture [286 x 95] intentionally omitted <==

==> picture [500 x 43] intentionally omitted <==

==> picture [377 x 35] intentionally omitted <==

==> picture [685 x 123] intentionally omitted <==

3

• Genetic Technologies - Leader in Genomics

• F Over a decade developing polygenic risk scores - for major oncological, metabolic and degenerative diseases

• F – a pioneer in the development of

• Strong scientific leadership under Dr Richard Allman polygenic risk scores

==> picture [204 x 95] intentionally omitted <==

• F Academic collaborations with some of the most prestigious academic institutions in the world

• F Delivering better outcomes - at a lower cost to the patient and the medical system

• F A robust IP portfolio with 15 patents granted, further 7 patent families pending

• F Dual listed - ASX (GTG) and Nasdaq (GENE)

• In 2020 we will offer the most comprehensive suite of polygenic risk assessment tests on the market

4

Products & Pipelines

==> picture [58 x 119] intentionally omitted <==

==> picture [286 x 95] intentionally omitted <==

==> picture [649 x 582] intentionally omitted <==

==> picture [431 x 503] intentionally omitted <==

==> picture [437 x 511] intentionally omitted <==

==> picture [1968 x 714] intentionally omitted <==

----- Start of picture text -----

CR Cancer Breast Cancer BRCA Panel
Prostate Diabetes CVD Melanoma Depression
----- End of picture text -----

Lynch Syndrome

==> picture [359 x 425] intentionally omitted <==

COVID-19

5

• COVID-19 SDR (Serious disease risk)

• World first genetic risk test that predicts your risk of hospitalisation & life threatening complications

• SDR

• Genetype for COVID-19 F World first

• F Combines genetic risk with clinical risk

• F Up to 111% better at identifying risk than clinical risk models on their own*

• F Simple oral swab test

• F Allows for remote screening

• F Accurate and low cost*

• F Designed to protect the vulnerable and first responders

• F Has the potential to be an alternative to a one size fits all lockdown strategy

• F Undergoing technical validation in GTG’s laboratory

• F Expected to be market ready Q1 2021***

• F In discussion with US labs who are able to scale up & distribute to whole of USA**

Indication

F Able to identify who is: - at risk of serious life threatening complications

• who needs to isolate as a precaution - needs to be prioritised for vaccination F To assist with management of individuals who are not suitable or have serious reservations with regards to being immunised F Offer medical intervention as a priority

GENETIC TESTING & REIMBURSEMENT (BRCA/Lynch Syndrome) Germline Testing F Inherited genes validated technology associated with high incidence of cancer risk F reimburable both in the US and Australia F NGS Sequencing - is increasingly used in medical management of patients and their immediate families F Allows for the seamless introduction of PRS tests into clinical management F BRCA Panel Lynch Syndrome Panel When combined with PRS, gives you 100% genetic risk cover F REIMBURSEMENT expected Lab validation plus certification & to be completed by end of 1H 2021 BREAST CANCER 100% Germline by Polygenic by Genetic BRCA = Genetype + Genetype 5% FAMILY HISTORY BUT NO HIGH-PENETRANCE Risk cover MUTATION SUCH AS BRCA 10% (BRCA) (PRS) PRS TEST COVERS 95% Germline by 85% OF WOMEN Polygenic by 100% NO FAMILY (GENETYPE FOR HISTORY Genetype BREAST CANCER) Genetype Genetic = + (Lynch (PRS) Risk cover Syndrome)

==> picture [38 x 40] intentionally omitted <==

• UP TO 100% GENETIC RISK COVER*

*UP TO 100% COVER = GERMLINE MUTATION TESTING PLUS POLYGENIC RISK SCORE

==> picture [76 x 13] intentionally omitted <==

----- Start of picture text -----

TESTING
----- End of picture text -----

genetype.com

7

Genetype for Mental Health Powered by Taliaz’s Predictix platform

==> picture [58 x 119] intentionally omitted <==

==> picture [286 x 95] intentionally omitted <==

Utilising a combination of:

genetic, metabolic, clinical & demographic background data in conjuction with AI & ML to create diagnostic and pharmacogenetic solutions that are 47% better than current best in class practises.

• F CE Marked, in the process of acquiring

• TGA approval, expected to be Market ready end of 1H 2021

• F Better outcomes due to superior

therapeutic drug selection

• F Addresses major unmet needs for a

• disease with a multi billion dollar global cost

• F Anticipated for market release in

• 2H 2021*

*Subject to regulatory approval

8

==> picture [2501 x 1677] intentionally omitted <==

----- Start of picture text -----

Expansion/Growth/Market Size
Lifestyle
ONCOLOGY
Ancestry
BC, CRC, PC, /Microbiome
Melanoma
GENETIC
TECHNOLOGIES
(Genetype)
CVD
Pharmoco-
Heart Disease
( ) genetics
IHD, AF
Mental
Metabolic
Health
Diseases (by Taliaz)
Diabetes
Germline
COVID-19 Testing
SDR (BRCA, Lynch
Syndrome)
Product development completed Future pipelines
----- End of picture text -----

9

• SALES & DISTRIBUTION by Region CLIA to sell into

• • Certified by US regulators the USA

• NATA , to sell

• • Certified by Australian regulators: into the Australian market

• Looking to commence CE certification with the

• view of entering the European market with our novel genetic risk tests in 2021

==> picture [58 x 119] intentionally omitted <==

==> picture [286 x 95] intentionally omitted <==

• SALES & DISTRIBUTION by Method

• CIT (Consumer initiated testing and online sales and marketing platform with medical supervision) launched in Australia & the USA in Q4 2020

• DTC (Direct to consumer testing with no medical supervision) including ancestry and gut microbiome testing scheduled Q2 2021

• BtoB sales via the medical profession

• Certifying reimbursible Germline testing platform

• Combined with an educational program to target health professionals mediated VR professional industry education content providers

10

• Corporate • Dual listed on ASX and the Nasdaq the worlds largest biotech exchange Listings In 2001 and 2005 respectively • 600 shares on the ASX equate to 1 ADR (American Depository Receipts) in the USA which are interchangeable via custodian bank of Mellon with 70% of stock held in the USA • 10 million ADR’s with extremely low float • August 2020 to October 2020 average trading value in USD $1.1m per day • ADR price USD $4.92 and share price $0.007 as at 9 December 2020 • Market cap of approximately AUD $58m as at 9 December 2020 • Current mandate with HC Wainright as USA bankers • Presented at JPMorgan biotech conference in January in San Francisco and HC Wainright virtual conference in July 2020 • Approximately AUD $18m cash with 24 months runway as at 30 September 2020

==> picture [189 x 95] intentionally omitted <==

11

Progress over the year

==> picture [58 x 119] intentionally omitted <==

==> picture [286 x 95] intentionally omitted <==

==> picture [2384 x 1337] intentionally omitted <==

----- Start of picture text -----

1Q 2020
Launched CIT
Australia 2Q 2020
Colorectal Cancer COVID-19 sdr test
3Q 2020
Market Release Pivoted and established the test
with target release this month
COVID-19 risk of
4Q 2020
hospitalisation
Test prototype
Cardiovascular
1H 2021
Prototype
Type 2 Diabetes COVID-19
Type 2 Diabetes
Market Release Prototype Market Release
COVID-19
Germline
Validation &Regulatory Approval
Market Release
High Density/Multitest
Melanoma
Market Release will
include the following:
Breast Cancer, Colorectal
Prostate Cancer
Cancer, CVD, T2D, Melanoma,
Prostate Cancer, COVID-19
Germline
BRCA/ Lynch Mental Health
Taliaz
Market Release
Mental Health
Taliaz
----- End of picture text -----

12

The next 12 months

==> picture [58 x 119] intentionally omitted <==

==> picture [286 x 95] intentionally omitted <==

• Complete development of high density multi disease tests to:

• Provide coverage of >70% mortality causes in western society using a single swab • Delivering low cost, accurate risk data

Establishing new divisions:

• Oncology

• Metabolic Diseases

• Cardiovascular Disease

• Mental Health (including cognitive decline)

• Pharmacogenomics (Pgx)

• General Wellness

• Commission Next Generation Sequencing (NGS)

• Establish products in related monogenic space

• Combine monogenic and polygenic testing under one integrated service to deliver up to 100% genetic risk cover

• Determine the feasability of a subscription service

• • Provides individuals with updates on their ongoing disease risk without the need

• to re-test for as little as $1 a day

• Leverage CIT Platform and Telehealth for Consumer Initiated Testing Expanding product offering with COVID-19 sdr Test and further

• product releases over the year

13